The New England Journal of Medicine: Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
ascopubs.org: The metabolic profiles of patients with autologous hematopoietic stem cell transplantation with graft versus host disease.
The metabolic profiles of patients with autologous hematopoietic stem cell transplantation with graft versus host disease.
In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD). A ...
ascopubs.org: Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
Fred Hutch: New drug regimen prevents both chronic and acute graft-versus-host disease
Graft-versus-host disease (GVHD) following liver transplantation remains a rare but devastating complication, characterised by donor immunocompetent cells initiating an immune attack against host ...
ascopubs.org: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
It’s possible to manage graft-versus-host disease (GVHD) with appropriate treatments. Your individualized treatment plan will depend on your symptoms, their severity, and the disease’s response to ...
Medical News Today: What are the signs and symptoms of graft-versus-host disease?
Skin, gastrointestinal, and liver symptoms are common manifestations of graft-versus-host disease (GVHD). The potentially life threatening complication is from allogeneic hematopoietic stem cell ...
MarketWatch: Orca Bio Announces Orca-T(R) Phase 3 Data Published in Blood Demonstrate Significant Improvement in Survival Free from Chronic Graft versus Host Disease in Patients with ...
Orca Bio Announces Orca-T(R) Phase 3 Data Published in Blood Demonstrate Significant Improvement in Survival Free from Chronic Graft versus Host Disease in Patients with ...